IL93576A - Pharmaceutical compositions of 4-phenyl-1,2,3, 4-tetrahydro-1-naphthalamine used to treat psychosis, inflammation and as immunosuppressants - Google Patents
Pharmaceutical compositions of 4-phenyl-1,2,3, 4-tetrahydro-1-naphthalamine used to treat psychosis, inflammation and as immunosuppressantsInfo
- Publication number
- IL93576A IL93576A IL9357690A IL9357690A IL93576A IL 93576 A IL93576 A IL 93576A IL 9357690 A IL9357690 A IL 9357690A IL 9357690 A IL9357690 A IL 9357690A IL 93576 A IL93576 A IL 93576A
- Authority
- IL
- Israel
- Prior art keywords
- tetrahydro
- naphthalenamine
- cis
- inflammation
- psychosis
- Prior art date
Links
- 206010061218 Inflammation Diseases 0.000 title claims abstract description 17
- 230000004054 inflammatory process Effects 0.000 title claims abstract description 17
- 208000028017 Psychotic disease Diseases 0.000 title claims description 19
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 15
- 229960003444 immunosuppressant agent Drugs 0.000 title description 6
- 239000003018 immunosuppressive agent Substances 0.000 title description 6
- 150000001875 compounds Chemical class 0.000 claims description 33
- 230000001506 immunosuppresive effect Effects 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 13
- 150000003839 salts Chemical class 0.000 claims description 12
- 206010062016 Immunosuppression Diseases 0.000 claims description 11
- 230000001939 inductive effect Effects 0.000 claims description 11
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 10
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 239000001257 hydrogen Substances 0.000 claims description 8
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 6
- 125000001246 bromo group Chemical group Br* 0.000 claims description 6
- DYLIWHYUXAJDOJ-OWOJBTEDSA-N (e)-4-(6-aminopurin-9-yl)but-2-en-1-ol Chemical compound NC1=NC=NC2=C1N=CN2C\C=C\CO DYLIWHYUXAJDOJ-OWOJBTEDSA-N 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- 125000003545 alkoxy group Chemical group 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 125000001153 fluoro group Chemical group F* 0.000 claims description 4
- 150000002431 hydrogen Chemical class 0.000 claims description 4
- 125000003854 p-chlorophenyl group Chemical group [H]C1=C([H])C(*)=C([H])C([H])=C1Cl 0.000 claims description 4
- VGKDLMBJGBXTGI-RGUGMKFQSA-N (1r)-4-(3,4-dichlorophenyl)-n-methyl-1,2,3,4-tetrahydronaphthalen-1-amine Chemical compound C([C@H](C1=CC=CC=C11)NC)CC1C1=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-RGUGMKFQSA-N 0.000 claims description 3
- VGKDLMBJGBXTGI-YVEFUNNKSA-N (1r,4s)-4-(3,4-dichlorophenyl)-n-methyl-1,2,3,4-tetrahydronaphthalen-1-amine Chemical compound C1([C@@H]2CC[C@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-YVEFUNNKSA-N 0.000 claims description 3
- SBRLSQHYWNDGMV-NSHDSACASA-N (4s)-4-(3,4-dichlorophenyl)-3,4-dihydro-2h-naphthalene-1,1-diamine Chemical compound C1([C@@H]2CCC(C3=CC=CC=C32)(N)N)=CC=C(Cl)C(Cl)=C1 SBRLSQHYWNDGMV-NSHDSACASA-N 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 3
- 230000000561 anti-psychotic effect Effects 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- LTKRQOGLVNJKBK-FVRDMJKUSA-N (4s)-4-(3,4-dichlorophenyl)-n,n-dimethyl-1,2,3,4-tetrahydronaphthalen-1-amine Chemical compound C1([C@@H]2CCC(C3=CC=CC=C32)N(C)C)=CC=C(Cl)C(Cl)=C1 LTKRQOGLVNJKBK-FVRDMJKUSA-N 0.000 claims description 2
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 2
- LLMOMOOMHWFGRN-MBIQTGHCSA-N (4s)-4-(4-chlorophenyl)-n-methyl-1,2,3,4-tetrahydronaphthalen-1-amine Chemical compound C1([C@@H]2CCC(C3=CC=CC=C32)NC)=CC=C(Cl)C=C1 LLMOMOOMHWFGRN-MBIQTGHCSA-N 0.000 claims 2
- VGKDLMBJGBXTGI-SJKOYZFVSA-N (1r,4r)-4-(3,4-dichlorophenyl)-n-methyl-1,2,3,4-tetrahydronaphthalen-1-amine Chemical compound C1([C@H]2CC[C@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJKOYZFVSA-N 0.000 claims 1
- VGKDLMBJGBXTGI-MTATWXBHSA-N (4r)-4-(3,4-dichlorophenyl)-n-methyl-1,2,3,4-tetrahydronaphthalen-1-amine Chemical compound C1([C@H]2CCC(C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-MTATWXBHSA-N 0.000 claims 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- IWNWWVPLTTUPBQ-UHFFFAOYSA-N 4-phenyl-1,2,3,4-tetrahydronaphthalen-1-amine Chemical class C12=CC=CC=C2C(N)CCC1C1=CC=CC=C1 IWNWWVPLTTUPBQ-UHFFFAOYSA-N 0.000 abstract description 4
- 230000027455 binding Effects 0.000 description 10
- HTSNFXAICLXZMA-UHFFFAOYSA-N 3-(1-propyl-3-piperidinyl)phenol Chemical compound C1N(CCC)CCCC1C1=CC=CC(O)=C1 HTSNFXAICLXZMA-UHFFFAOYSA-N 0.000 description 9
- 239000000872 buffer Substances 0.000 description 8
- 210000004556 brain Anatomy 0.000 description 6
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 5
- 230000005764 inhibitory process Effects 0.000 description 5
- 238000001727 in vivo Methods 0.000 description 4
- 239000000203 mixture Substances 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 108010085082 sigma receptors Proteins 0.000 description 3
- 239000000935 antidepressant agent Substances 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 238000009395 breeding Methods 0.000 description 2
- 230000001488 breeding effect Effects 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 2
- 239000002287 radioligand Substances 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 125000004189 3,4-dichlorophenyl group Chemical group [H]C1=C([H])C(Cl)=C(Cl)C([H])=C1* 0.000 description 1
- 208000019901 Anxiety disease Diseases 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- FTHCZYMFYCBWMW-UHFFFAOYSA-N Cl.CNCO.CNCO.CNCO Chemical compound Cl.CNCO.CNCO.CNCO FTHCZYMFYCBWMW-UHFFFAOYSA-N 0.000 description 1
- 206010014557 Emotional poverty Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 229920002873 Polyethylenimine Polymers 0.000 description 1
- 201000004681 Psoriasis Diseases 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 206010041243 Social avoidant behaviour Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000005013 brain tissue Anatomy 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 125000002147 dimethylamino group Chemical group [H]C([H])([H])N(*)C([H])([H])[H] 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 230000010807 negative regulation of binding Effects 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- VOKSWYLNZZRQPF-GDIGMMSISA-N pentazocine Chemical compound C1C2=CC=C(O)C=C2[C@@]2(C)[C@@H](C)[C@@H]1N(CC=C(C)C)CC2 VOKSWYLNZZRQPF-GDIGMMSISA-N 0.000 description 1
- 229960005301 pentazocine Drugs 0.000 description 1
- 238000003359 percent control normalization Methods 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 206010039073 rheumatoid arthritis Diseases 0.000 description 1
- 230000000698 schizophrenic effect Effects 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Transplantation (AREA)
- Psychiatry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/320,014 US4981870A (en) | 1989-03-07 | 1989-03-07 | Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL93576A0 IL93576A0 (en) | 1990-11-29 |
| IL93576A true IL93576A (en) | 1995-12-08 |
Family
ID=23244506
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL9357690A IL93576A (en) | 1989-03-07 | 1990-02-28 | Pharmaceutical compositions of 4-phenyl-1,2,3, 4-tetrahydro-1-naphthalamine used to treat psychosis, inflammation and as immunosuppressants |
Country Status (17)
| Country | Link |
|---|---|
| US (2) | US4981870A (de) |
| EP (1) | EP0386997B1 (de) |
| JP (2) | JPH0714870B2 (de) |
| KR (1) | KR920005810B1 (de) |
| AT (1) | ATE150299T1 (de) |
| AU (1) | AU610036B2 (de) |
| CA (1) | CA2011428C (de) |
| DE (1) | DE69030212T2 (de) |
| DK (1) | DK0386997T3 (de) |
| HU (1) | HU221624B1 (de) |
| IE (1) | IE81047B1 (de) |
| IL (1) | IL93576A (de) |
| MY (1) | MY106272A (de) |
| NZ (1) | NZ232800A (de) |
| PH (1) | PH26542A (de) |
| PT (1) | PT93351B (de) |
| ZA (1) | ZA901743B (de) |
Families Citing this family (51)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4981870A (en) * | 1989-03-07 | 1991-01-01 | Pfizer Inc. | Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants |
| AU658134B2 (en) * | 1989-12-28 | 1995-04-06 | Virginia Commonwealth University | Sigma receptor ligands and the use thereof |
| ES2060547B1 (es) * | 1992-06-04 | 1995-06-16 | Ferrer Int | Mejoras en el objeto de la patente de invencion n/ 9201158 que se refiere a "procedimiento de obtencion de nuevos derivados de la 4-bencilpiperidina". |
| US6087346A (en) * | 1993-06-23 | 2000-07-11 | Cambridge Neuroscience, Inc. | Sigma receptor ligands and the use thereof |
| ES2074946B1 (es) * | 1993-07-19 | 1996-06-16 | Ferrer Int | Nuevos compuestos derivados de la 1,2-etanodiamina-n,n,n',n'-tetrasustituida. |
| US20040208926A1 (en) * | 1997-07-01 | 2004-10-21 | Pfizer Inc | Solubilized sertraline compositions |
| US20030133974A1 (en) * | 1997-07-01 | 2003-07-17 | Curatolo William John | Encapsulated solution dosage forms of sertraline |
| HUP0002296A3 (en) | 1997-07-01 | 2001-11-28 | Pfizer | Sertraline salts and sustained-release dosage forms of sertraline |
| CA2395231C (en) | 1999-12-23 | 2006-08-15 | Pfizer Products Inc. | Hydrogel-driven layered drug dosage form |
| AU2002322720B2 (en) | 2001-07-25 | 2008-11-13 | Raptor Pharmaceutical Inc. | Compositions and methods for modulating blood-brain barrier transport |
| US6988556B2 (en) * | 2002-02-19 | 2006-01-24 | Halliburton Energy Services, Inc. | Deep set safety valve |
| AU2003272461A1 (en) * | 2002-09-16 | 2004-04-30 | Sepracor Inc. | TREATMENT OF CNS DISORDERS WITH trans 4-(3,4-DICHLOROPHENYL)-1,2,3,4-TETRAHYDRO-N-METHYL-1-NAPTHALENAMINE |
| US8134029B2 (en) | 2002-09-16 | 2012-03-13 | Sunovion Pharmaceuticals Inc. | Treatment of CNS disorders with trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine |
| CN100584818C (zh) * | 2002-09-16 | 2010-01-27 | 塞普拉科公司 | 用反式4-(3,4-二氯苯基)-1,2,3,4-四氢-1-萘胺及其甲酰胺治疗cns病症 |
| KR101165549B1 (ko) * | 2002-09-16 | 2012-07-19 | 선오비온 파마슈티컬스 인코포레이티드 | 트랜스 ４－（３，４－디클로로페닐）－１，２，３，４－테트라하이드로－１－나프탈렌아민을 사용한 ｃｎｓ 장애의 치료 |
| US20040220153A1 (en) * | 2002-09-24 | 2004-11-04 | Jost-Price Edward Roydon | Methods and reagents for the treatment of diseases and disorders associated with increased levels of proinflammatory cytokines |
| CN1922149A (zh) * | 2003-12-29 | 2007-02-28 | 塞普拉科公司 | 吡咯和吡唑daao抑制剂 |
| CN102379684B (zh) | 2005-04-28 | 2014-11-19 | 普罗透斯数字保健公司 | 药物信息系统 |
| CA2614282A1 (en) | 2005-07-06 | 2007-01-11 | Sepracor Inc. | Combinations of eszopiclone and trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-n-methyl-1-napthalenamine or trans 4-(3,4-dichlorophenyl)-1,2,3,4-tetrahydro-1-napthalenamine, and methods of treatment of menopause and mood, anxiety, and cognitive disorders |
| US7985756B2 (en) | 2005-10-21 | 2011-07-26 | Braincells Inc. | Modulation of neurogenesis by PDE inhibition |
| WO2007053596A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| KR101381768B1 (ko) * | 2006-01-06 | 2014-04-07 | 선오비온 파마슈티컬스 인코포레이티드 | 테트랄론-기재 모노아민 재흡수 저해제 |
| EP1976513B1 (de) | 2006-01-06 | 2016-08-24 | Sunovion Pharmaceuticals Inc. | Cycloalkylamine als monoamin-wiederaufnahmehemmer |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| PT2816024T (pt) | 2006-03-31 | 2017-10-20 | Sunovion Pharmaceuticals Inc | Aminas quirais |
| WO2007134077A2 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
| WO2007134136A2 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| KR20090015089A (ko) * | 2006-05-31 | 2009-02-11 | 세프라코 아이엔시. | 트랜스 4-(3,4-디클로로페닐)-1,2,3,4-테트라하이드로-1-나프탈렌아민 및 그의 포름아미드에 의한 통증장애 치료방법 |
| US7884124B2 (en) * | 2006-06-30 | 2011-02-08 | Sepracor Inc. | Fluoro-substituted inhibitors of D-amino acid oxidase |
| US7579370B2 (en) * | 2006-06-30 | 2009-08-25 | Sepracor Inc. | Fused heterocycles |
| EP2068872A1 (de) | 2006-09-08 | 2009-06-17 | Braincells, Inc. | Kombinationen mit einem 4-acylaminopyridin-derivat |
| KR20090071598A (ko) | 2006-09-18 | 2009-07-01 | 랩터 파마슈티컬 인코포레이티드 | 수용체 결합 단백질(ｒａｐ)-접합체 투여에 의한 간 질환의 치료 |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| US20080082066A1 (en) * | 2006-10-02 | 2008-04-03 | Weyerhaeuser Co. | Crosslinked carboxyalkyl cellulose fibers having non-permanent and temporary crosslinks |
| FR2909376A1 (fr) * | 2006-11-30 | 2008-06-06 | Cerep Sa | Procedes de preparation de la desmethulsertraline ou d'un de ses sels pharmaceutiquement acceptables |
| JP2010516697A (ja) * | 2007-01-18 | 2010-05-20 | セプラコール インク． | Ｄ−アミノ酸オキシダーゼ阻害剤 |
| US7902252B2 (en) * | 2007-01-18 | 2011-03-08 | Sepracor, Inc. | Inhibitors of D-amino acid oxidase |
| WO2008151156A1 (en) | 2007-05-31 | 2008-12-11 | Sepracor Inc. | Phenyl substituted cycloalkylamines as monoamine reuptake inhibitors |
| US20100120740A1 (en) * | 2008-08-07 | 2010-05-13 | Sepracor Inc. | Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase |
| WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| ES2942923T3 (es) | 2009-05-06 | 2023-06-07 | Laboratory Skin Care Inc | Composiciones de administración dérmica que comprenden complejos de agente activo-partículas de fosfato de calcio y métodos de uso de las mismas |
| US20110034434A1 (en) * | 2009-08-07 | 2011-02-10 | Sepracor Inc. | Prodrugs of fused heterocyclic inhibitors of d-amino acid oxidase |
| US20120077778A1 (en) | 2010-09-29 | 2012-03-29 | Andrea Bourdelais | Ladder-Frame Polyether Conjugates |
| WO2014078568A1 (en) | 2012-11-14 | 2014-05-22 | The Johns Hopkins University | Methods and compositions for treating schizophrenia |
| WO2014144663A1 (en) | 2013-03-15 | 2014-09-18 | The Johns Hopkins University | Methods and compositions for improving cognitive function |
| EP2968220B1 (de) | 2013-03-15 | 2021-05-05 | Agenebio, Inc. | Verfahren und zusammensetzungen zur verbesserung von kognitiven funktionen |
| KR20170003677A (ko) * | 2014-05-13 | 2017-01-09 | 선오비온 파마슈티컬스 인코포레이티드 | Adhd의 치료를 위한 다소트랄린의 방법 및 조성물 |
| JP2017515849A (ja) * | 2014-05-13 | 2017-06-15 | サノビオン ファーマシューティカルズ インクＳｕｎｏｖｉｏｎ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｉｎｃ． | Ａｄｈｄを治療するためのダソトラリン用量および治療方法 |
| WO2016046669A2 (en) * | 2014-09-27 | 2016-03-31 | Mohan M Alapati | Compositions and methods for the treatment of depression and neurological diseases |
| NZ738682A (en) | 2015-05-22 | 2022-01-28 | Agenebio Inc | Extended release pharmaceutical compositions of levetiracetam |
| FR3071726B1 (fr) * | 2017-09-29 | 2020-09-04 | Univ Paris Sud | Agents inhibant la proteine tctp pour le traitement de maladies proliferatives et de maladies infectieuses |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB1420472A (en) * | 1972-09-27 | 1976-01-07 | Pfizer | Aminophenyltetralin compounds |
| US4536518A (en) * | 1979-11-01 | 1985-08-20 | Pfizer Inc. | Antidepressant derivatives of cis-4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine |
| JPS59497B2 (ja) * | 1979-11-01 | 1984-01-07 | フアイザ−・インコ−ポレ−テツド | トランス−４−フエニル−１，２，３，４−テトラヒドロ−１−ナフタレンアミンの抗抑うつ性誘導体 |
| US4792448A (en) * | 1987-06-11 | 1988-12-20 | Pfizer Inc. | Generic zero order controlled drug delivery system |
| US4981870A (en) * | 1989-03-07 | 1991-01-01 | Pfizer Inc. | Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of psychosis, inflammation and as immunosuppressants |
-
1989
- 1989-03-07 US US07/320,014 patent/US4981870A/en not_active Expired - Lifetime
-
1990
- 1990-02-28 IL IL9357690A patent/IL93576A/en not_active IP Right Cessation
- 1990-03-05 MY MYPI90000347A patent/MY106272A/en unknown
- 1990-03-05 CA CA002011428A patent/CA2011428C/en not_active Expired - Fee Related
- 1990-03-06 AU AU50796/90A patent/AU610036B2/en not_active Ceased
- 1990-03-06 DK DK90302365.3T patent/DK0386997T3/da active
- 1990-03-06 AT AT90302365T patent/ATE150299T1/de not_active IP Right Cessation
- 1990-03-06 DE DE69030212T patent/DE69030212T2/de not_active Expired - Fee Related
- 1990-03-06 PT PT93351A patent/PT93351B/pt not_active IP Right Cessation
- 1990-03-06 HU HU9001325A patent/HU221624B1/hu not_active IP Right Cessation
- 1990-03-06 JP JP2054802A patent/JPH0714870B2/ja not_active Expired - Fee Related
- 1990-03-06 EP EP90302365A patent/EP0386997B1/de not_active Expired - Lifetime
- 1990-03-06 KR KR1019900002912A patent/KR920005810B1/ko not_active Expired
- 1990-03-06 NZ NZ232800A patent/NZ232800A/en unknown
- 1990-03-07 PH PH40157A patent/PH26542A/en unknown
- 1990-03-07 ZA ZA901743A patent/ZA901743B/xx unknown
- 1990-03-07 IE IE79890A patent/IE81047B1/en not_active IP Right Cessation
- 1990-12-05 US US07/622,308 patent/US5061728A/en not_active Expired - Lifetime
-
1994
- 1994-07-25 JP JP6172929A patent/JP3020808B2/ja not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| HUT59000A (en) | 1992-04-28 |
| EP0386997A2 (de) | 1990-09-12 |
| EP0386997A3 (de) | 1992-04-29 |
| DE69030212T2 (de) | 1997-06-26 |
| DK0386997T3 (da) | 1997-04-14 |
| CA2011428C (en) | 1994-11-08 |
| EP0386997B1 (de) | 1997-03-19 |
| MY106272A (en) | 1995-04-29 |
| HU901325D0 (en) | 1990-05-28 |
| PT93351A (pt) | 1990-11-07 |
| ATE150299T1 (de) | 1997-04-15 |
| US5061728A (en) | 1991-10-29 |
| NZ232800A (en) | 1997-07-27 |
| HU221624B1 (hu) | 2002-12-28 |
| KR920005810B1 (ko) | 1992-07-20 |
| JPH02300121A (ja) | 1990-12-12 |
| ZA901743B (en) | 1991-10-30 |
| JPH07173056A (ja) | 1995-07-11 |
| AU610036B2 (en) | 1991-05-09 |
| JPH0714870B2 (ja) | 1995-02-22 |
| IL93576A0 (en) | 1990-11-29 |
| JP3020808B2 (ja) | 2000-03-15 |
| PH26542A (en) | 1992-08-19 |
| IE900798L (en) | 1990-09-07 |
| KR900013949A (ko) | 1990-10-22 |
| PT93351B (pt) | 1996-03-29 |
| DE69030212D1 (de) | 1997-04-24 |
| IE81047B1 (en) | 1999-12-01 |
| CA2011428A1 (en) | 1990-09-07 |
| AU5079690A (en) | 1990-09-20 |
| US4981870A (en) | 1991-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5061728A (en) | Use of 4-phenyl-1,2,3,4-tetrahydro-1-naphthalenamine derivatives in the treatment of inflammation and as immunosuppressants | |
| US10188613B2 (en) | Exo-S-mecamylamine formulation and use in treatment | |
| KR100412154B1 (ko) | N-프로파길-1-아미노인단의r-에난시오머,염,및그들의조성물의사용 | |
| US20020016370A1 (en) | Exo-R-mecamylamine formulation and use in treatment | |
| CS227019B2 (en) | Method of preparing (-)-n-methyl-3-(2-methylphenyloxy)-3-phenylpropylamine | |
| HU226138B1 (en) | R-enantiomer of n-propargyl-1-aminoindan, salts, compositions and uses thereof | |
| CA2138998A1 (en) | Methods and compositions for treating depression and other disorders using optically pure(-) sibutramine | |
| EP0708639A1 (de) | Verfahern und zusammensetzungen zur behandlumng von depression und anderen erkrankungen unter verwendung von optisch-reienem sibuttramin | |
| Korsgaard et al. | The Effect of Tetrahydroisoxazolopyridinol (THIP) in Tardive Dyskinesia: A New β-Aminobutyric Acid Agonist | |
| AU608922B2 (en) | Method for the treatment of anxiety | |
| JPH05132430A (ja) | 薬物従属症及び禁断症状の治療に関するグリシン／ｎｍｄａレセプターリガンドの用法 | |
| WO2003002059A2 (en) | Tolterodine metabolites | |
| US6552087B1 (en) | Therapeutic agent comprising (+)-sibutramine | |
| DK174506B1 (da) | Anvendelse af en forbindelse til fremstilling af et farmaceutisk præparat til behandling af fibromyalgia | |
| US4053637A (en) | Compounds of diphenylcyclopentylamine type and methods for their uses | |
| US4141993A (en) | Compounds of diphenylcyclopentylamine type and methods for their preparation | |
| DE3686538T2 (de) | Verwendung von dibenz(cd,f)indol-derivaten zur praevention vom alkoholmissbrauch. | |
| US3772440A (en) | Method for the treatment of parkinsonism and depression | |
| Wong et al. | Fluoxetine (Prozac) and Other Selective Serotonin Uptake Inhibitors | |
| Shytle et al. | Exo-S-mecamylamine formulation and use in treatment | |
| Wong et al. | DEVELOPMENT OF ANTIDEPRESSANT DRUGS | |
| KR20010071780A (ko) | Ｇａｂａ 유사체에 의한 신산통의 치료 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| MM9K | Patent not in force due to non-payment of renewal fees | ||
| MM9K | Patent not in force due to non-payment of renewal fees |